Medical Device News Magazine

Mount Sinai Health System Launches COVID-19 Saliva Testing Program to Protect Public Health as Business and Leisure Activities Reopen

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

April 5, 2021

As businesses look for ways to safely reopen, Mount Sinai Health System announced today the launch of the Mount Sinai COVID-19 PCR Saliva Testing program to provide quick, noninvasive, and precise testing to support safety for businesses and leisure activities in New York.

The Program offers an easy, effective, and accurate COVID-19 test for the public. Mount Sinai is an official partner of the New York State Excelsior Pass program, a new effort to fast-track the opening of theaters, stadiums, and other businesses.

Using advanced laboratory technology that detects the presence of the virus that causes COVID-19 in saliva, the Mount Sinai program guarantees final results within 48 hours, although the vast majority of results return within 24 hours. The program offers four convenient testing locations in Manhattan: Mount Sinai Business Health at 226 West 14th Street, Mount Sinai Doctors at Health Quarters Noho at 632 Broadway, Mount Sinai Doctors at 55 East 34th Street, and Mount Sinai Express Care at 1190 Fifth Avenue. Results are transmitted securely and rapidly to the Excelsior Pass app, allowing ease of admission to venues that use the app, such as theaters and stadiums.

“Mount Sinai has shown extraordinary commitment and leadership in scientific and clinical efforts to beat this pandemic. We developed one of the first highly sensitive antibody tests, pioneered innovative therapies to treat COVID-19, and are researching the lingering effects suffered by ‘long-haulers.’ This program is designed to help our community in slowing transmission and getting us back to normal,” said David L. Reich, MD, President and Chief Operating Officer, The Mount Sinai Hospital. “The Mount Sinai program will make testing more accessible and convenient so as to protect public health. We are proud to partner with New York State and to be a provider of choice for testing.”

Mount Sinai’s saliva test is an easy, safe, and accurate alternative to the more commonly used nasal and nasopharyngeal swab tests but uses the same, highly accurate polymerase chain reaction (PCR) technology. It can also be administered to young children. If a saliva sample cannot be obtained, or if someone has eaten or drunk something prior to the test, a nasal swab test can be performed instead. The test can also be used for business or leisure travel purposes or return-to-work authorization. To schedule an appointment, visit https://www.mountsinai.org/lp/covid19-saliva-test.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”